The FDA Finally Updates Its Stance on Estrogen, Here’s What Women Should Know #fda #estrogen

Name: The FDA Finally Updates Its Stance on Estrogen, Here’s What Women Should Know #fda #estrogen
Uploaded: 2025-11-25T01:02:09+00:00
Duration: 55 s
Channel: Dr. Charles Mok
Description: A short public-health commentary by Dr. Charles Mok arguing that the medical response to a subgroup finding from the Women’s Health Initiative caused…

25 Nov 2025 · 1 min

Watch on YouTube

0:55

A short public-health commentary by Dr. Charles Mok arguing that the medical response to a subgroup finding from the Women’s Health Initiative caused decades of over-treatment for menopause. The speaker asserts that more recent U.S. studies (within the last five years) show that HRT regimens with testosterone as the primary driver are associated with a roughly 30–70% reduction in breast cancer rates, and notes the FDA is removing the black-box warning from estrogen-containing products. The overall stance is critical of past overreaction and supportive of updated regulatory guidance.

Chapters

Probably the biggest disservice to women's health care in the last century was how we responded to this very narrow segment of the Women's Health Initiative study. We reacted to that one subgroup taking a certain synthetic drug at a certain time in our life that we shouldn't have done. We changed the entire face of Women's Healthcare for 23 years. We come up with a whole multibillion dollar drug industry to treat the symptoms of menopause when we can use generic medication to treat the cause. And we're looking at even in US Studies more recently published in the last five years have shown that women on hormone replacement therapy with testosterone as the primary driver have about a 30 to 70% reduction in breast cancer rates. 30 to 70%. This kind of nails the coffin in the idea that hormones cause breast cancer. The FDA is removing black box warning from all estrogen containing products. Let's talk about it.